IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>Nikkei <a href="https://asia.nikkei.com/Business/Business-deals/Japan-state-backed-fund-looks-to-buy-top-photoresist-maker-JSR" target="_blank" rel="noopener">reports</a> that Japan Investment Corporation (JIC) is in talks to acquire <a href="https://www.smartkarma.com/entities/jsr-corp" target="_blank" data-smartkarma-citation="entities:17620:1" rel="noopener">JSR Corp (4185 JP)</a> for around JPY1 trillion (US$7 billion) through a tender offer.</li>
<li>JSR responded, "<em>No decision has been made at this moment, although JSR is considering this matter.</em>” The Board will discuss the proposal on Monday.</li>
<li>Minorities will be supportive as the JPY1 trillion valuation implies a tender price of JPY4,850 per share, a 50% premium to the last close and an all-time share price high.   </li>
</ul>


Nikkei reports that Japan Investment Corporation (JIC) is in talks to acquire JSR Corp (4185 JP) for around JPY1 trillion (US$7 billion) through a tender offer.
JSR responded, "No decision has been made at this moment, although JSR is considering this matter.” The Board will discuss the proposal on Monday.
Minorities will be supportive as the JPY1 trillion valuation implies a tender price of JPY4,850 per share, a 50% premium to the last close and an all-time share price high.   


JSR Corporation (4185 JP): JIC’s Tender Offer Looming?

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Capital Markets

<ul><li>DuPont de Nemours had a challenging 2023 first quarter as organic revenue declined by 3%, although there was broad demand strength in areas including water, automotive, aerospace, and healthcare.</li><li>DuPont de Nemours recently announced a $1.75 billion definitive agreement to acquire Spectrum, a leading manufacturer of critical components and devices for medical end markets.</li><li>We give DuPont de Nemours, Inc. a 'Hold' rating with a revised target price.</li></ul>

DuPont de Nemours had a challenging 2023 first quarter as organic revenue declined by 3%, although there was broad demand strength in areas including water, automotive, aerospace, and healthcare.DuPont de Nemours recently announced a $1.75 billion definitive agreement to acquire Spectrum, a leading manufacturer of critical components and devices for medical end markets.We give DuPont de Nemours, Inc. a 'Hold' rating with a revised target price.

DuPont de Nemours Inc.: Acquisition Of Spectrum Plastics & Other Key Drivers

<ul><li>DuPont had a mixed fourth quarter and its revenues were below analyst expectations but the company managed to deliver an earnings beat.</li><li>The company has also succeeded in enhancing its grip on industrial-end markets such as healthcare and aerospace.</li><li>There was a strong pricing growth as well that helped mitigate the impact of inflation.</li></ul>

DuPont had a mixed fourth quarter and its revenues were below analyst expectations but the company managed to deliver an earnings beat.The company has also succeeded in enhancing its grip on industrial-end markets such as healthcare and aerospace.There was a strong pricing growth as well that helped mitigate the impact of inflation.

Du Pont De Nemours and Company: Major Drivers

<ul><li>DuPont’s stock price has surged past our target price and is witnessing a strong momentum after the company posted a solid set of results this quarter in an extremely challenging environment.</li><li>The revenue growth of the company included solid organic growth.</li><li>We provide the stock of DuPont with a ‘Buy’ rating and a revision in the target price.</li></ul>

DuPont’s stock price has surged past our target price and is witnessing a strong momentum after the company posted a solid set of results this quarter in an extremely challenging environment.The revenue growth of the company included solid organic growth.We provide the stock of DuPont with a ‘Buy’ rating and a revision in the target price.

DuPont de Nemours: DuPont Liveo Healthcare Solutions In China & Other Drivers

<ul><li>DuPont delivered a solid set of quarterly results in a challenging environment.</li><li>The Roger acquisition also made great progress and DuPont is supposed to close the deal in the next quarter.</li><li>Also, DuPont continues to actively invest in both introducing new products and advancing the technology within its existing product portfolio.</li></ul>

DuPont delivered a solid set of quarterly results in a challenging environment.The Roger acquisition also made great progress and DuPont is supposed to close the deal in the next quarter.Also, DuPont continues to actively invest in both introducing new products and advancing the technology within its existing product portfolio.

DuPont de Nemours: Micromax Launch & Other Drivers

United States

DuPont de Nemours, Inc. operates as a chemical company. The Company offers elastomeric photopolymer printing plates, structural and elastic adhesives, fluids, reinforcing composites, foams, coatings, rubber and elastomers, topical ingredients, food ingredients, animal nutrition, biomaterials, water purification technologies, and fibers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DuPont (DD US)

JSR Corporation (4185 JP): JIC’s Tender Offer Looming?

Nikkei reports the JIC is in talks to acquire JSR for around JPY1 trillion. The rumoured offer implies a 50% premium to the last close and an all...

Arun George

DuPont de Nemours Inc.: Acquisition Of Spectrum Plastics & Other Key Drivers

DuPont de Nemours had a challenging 2023 first quarter as organic revenue declined by 3%, although there was broad demand strength in areas...

Baptista Research

Du Pont De Nemours and Company: Major Drivers

DuPont had a mixed fourth quarter and its revenues were below analyst expectations but the company managed to deliver an earnings beat. The...

Baptista Research

DuPont de Nemours: DuPont Liveo Healthcare Solutions In China & Other Drivers

DuPont’s stock price has surged past our target price and is witnessing a strong momentum after the company posted a solid set of results this...

Baptista Research

DuPont de Nemours: Micromax Launch & Other Drivers

DuPont delivered a solid set of quarterly results in a challenging environment. The Roger acquisition also made great progress and DuPont is...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)